Log In
Print
BCIQ
Print
Print this Print this
 

PRS-110

  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionAnticalin targeting c-Met receptor tyrosine kinase
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Zydus Cadila Group


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today